日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Asia-Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo

以转化科学和定量临床药理学为支撑的包容亚洲的临床研究与开发:迈向挑战现状的文化

Venkatakrishnan, Karthik; Gupta, Neeraj; Smith, Patrick F; Lin, Tiffany; Lineberry, Neil; Ishida, Tatiana; Wang, Lin; Rogge, Mark

Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants

利扎替尼(Rilzabrutinib),一种可逆共价布鲁顿酪氨酸激酶抑制剂:在健康受试者中的吸收、代谢、排泄和绝对生物利用度

Ucpinar, Sibel; Smith, Patrick F; Long, Li; Li, Fujun; Yan, Hui; Wadhwa, Jyoti; Chu, Katherine A; Shu, Jin; Nunn, Philip; Li, Mengyao

Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results

口服核苷类似物鲁米西他滨治疗呼吸道合胞病毒(RSV)感染住院婴儿的安全性、有效性和药代动力学结果

Oey, Abbie; McClure, Matthew; Symons, Julian A; Chanda, Sushmita; Fry, John; Smith, Patrick F; Luciani, Kathia; Fayon, Michael; Chokephaibulkit, Kulkanya; Uppala, Rattapon; Bernatoniene, Jolanta; Furuno, Kenji; Stanley, Thorsten; Huntjens, Dymphy; Witek, James

Assessing the Combined Public Health Impact of Pharmaceutical Interventions on Pandemic Transmission and Mortality: An Example in SARS CoV-2

评估药物干预措施对大流行传播和死亡率的综合公共卫生影响:以SARS-CoV-2为例

Kamal, Mohamed A; Kuznik, Andreas; Qi, Luyuan; Więcek, Witold; Hussein, Mohamed; Hassan, Hazem E; Patel, Kashyap; Obadia, Thomas; Toroghi, Masood Khaksar; Conrado, Daniela J; Al-Huniti, Nidal; Casciano, Roman; O'Brien, Meagan P; Barnabas, Ruanne V; Cohen, Myron S; Smith, Patrick F

A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects

一项全面的QTc研究,旨在评估口服利扎替尼单独给药以及与利托那韦联合给药对健康受试者的影响。

Ucpinar, Sibel; Darpo, Borje; Neale, Ann; Nunn, Philip; Shu, Jin; Chu, Katherine A; Kavanagh, Marianne; Xue, Hongqi; Phiasivongsa, Pasit; Thomas, Dolca; Smith, Patrick F

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

评估 BTK 抑制剂 tolebrutinib (PRN2246, SAR442168) 的安全性、暴露量和药效学的 1 期临床试验

Owens, Timothy D; Smith, Patrick F; Redfern, Andrew; Xing, Yan; Shu, Jin; Karr, Dane E; Hartmann, Sonja; Francesco, Michelle R; Langrish, Claire L; Nunn, Philip A; Gourlay, Steven G

An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study.

评估超治疗剂量的inclisiran对健康志愿者心脏复极化的影响:一项 I 期随机研究

Kallend David, Mason Jay, Smith Patrick F, Koren Michael J, Stoekenbroek Robert, He YanLing, Wijngaard Peter

Model-Informed Drug Development for Anti-Infectives: State of the Art and Future

基于模型的抗感染药物研发:现状与展望

Rayner, Craig R; Smith, Patrick F; Andes, David; Andrews, Kayla; Derendorf, Hartmut; Friberg, Lena E; Hanna, Debra; Lepak, Alex; Mills, Edward; Polasek, Thomas M; Roberts, Jason A; Schuck, Virna; Shelton, Mark J; Wesche, David; Rowland-Yeo, Karen

Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19

加速对新冠肺炎现有联合疗法进行临床评估

Rayner, Craig R; Dron, Louis; Park, Jay J H; Decloedt, Eric H; Cotton, Mark F; Niranjan, Vis; Smith, Patrick F; Dodds, Michael G; Brown, Fran; Reis, Gilmar; Wesche, David; Mills, Edward J

Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics

跨学科药物计量学将奥司他韦药理学、流感流行病学和卫生经济学联系起来,为大流行期间的抗病毒药物使用提供信息

Kamal, Mohamed A; Smith, Patrick F; Chaiyakunapruk, Nathorn; Wu, David B C; Pratoomsoot, Chayanin; Lee, Kenneth K C; Chong, Huey Yi; Nelson, Richard E; Nieforth, Keith; Dall, Georgina; Toovey, Stephen; Kong, David C M; Kamauu, Aaron; Kirkpatrick, Carl M; Rayner, Craig R